September 17, 2019

Ryan M. Confer
Chief Financial Officer
Genprex, Inc.
1601 Trinity Street, Bldg B
Suite 3.322
Austin, TX 78712

       Re: Genprex, Inc.
           Form 10-K for the Fiscal Year Ended December 31, 2018
           Filed April 1, 2019
           Form 10-Q for the Quarterly Period Ended June 30, 2019
           Filed August 13, 2019
           File No. 001-38244

Dear Mr. Confer:

       We have reviewed your filings and have the following comments. In some
of our
comments, we may ask you to provide us with information so we may better
understand your
disclosure.

       Please respond to these comments within ten business days by providing
the requested
information or advise us as soon as possible when you will respond. If you do
not believe our
comments apply to your facts and circumstances, please tell us why in your
response.

       After reviewing your response to these comments, we may have additional
comments.

Form 10-K for the Fiscal Year Ended December 31, 2018

Item 9A. Controls and Procedures, page 84

1.    Please tell us how you determined that a conclusion that your internal
control over
      financial reporting (ICFR) was not effective as of December 31, 2018, did
not impact your
      conclusion regarding the effectiveness of your disclosure controls and
procedures (DCP),
      as defined in Exchange Act Rules 13a-15(e) and 15d-15(e). Please refer to
SEC Release
      No. 33-8238, Final Rule: Management's Report on Internal Control Over
Financial
      Reporting and Certification of Disclosure in Exchange Act Periodic
Reports, which states
      that disclosure controls and procedures will include those components of
internal control
      over financial reporting that provide reasonable assurances that
transactions are recorded
      as necessary to permit preparation of financial statements in accordance
with generally
 Ryan M. Confer
Genprex, Inc.
September 17, 2019
Page 2
         accepted accounting principles. Please explain how you determined that
the material
         weaknesses in your ICFR was not one of the components of ICFR that is
also included in
         disclosure controls and procedures. This comment also applies to your
DCP conclusions
         contained in your Forms 10-Q for the quarterly periods ended March 31
and June 30,
         2019.
Financial Statements
Notes to Financial Statements
Note 5 - Equity, page F-10

2.       You state on page F-12 "The per-share fair values of these options
range from $0.001 to
         $7.93, based on Black-Scholes-Merton pricing models with the following
         assumptions," however you do not disclose the assumptions. Please
provide us the
         assumptions required to be disclosed by ASC 718-10-50 and tell us your
consideration of
         disclosing the assumptions. In addition, ASC-718-10-50 requires
disclosure of "As of the
         latest balance sheet date presented, the total compensation cost
related to nonvested
         awards not yet recognized and the weighted-average period over which
it is expected to be
         recognized." Please direct us to or provide us this information and
tell us your
         consideration of disclosing this information.
Form 10-Q for the Quarterly Period Ended June 30, 2019

Item 6. Exhibits, page 52

3.       Please amend your filing to provide new certifications filed as
Exhibits 31.1 and 31.2
         to conform exactly to that provided in Item 601(b)(31) of Regulation
S-K as it relates to
         internal controls over financial reporting (ICFR). In this regard, the
introductory sentence
         in paragraph 4 should refer to ICFR as defined in the Exchange Act and
certification 4(b)
         should discuss your obligations related to ICFR. Similarly, please
amend the 10-Q for the
         quarterly period ended March 31, 2019.
        We remind you that the company and its management are responsible for
the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action
or absence of
action by the staff.

      You may contact Vanessa Robertson at 202-551-3649 or Lisa Vanjoske at
202-551-
3614 with any questions.



FirstName LastNameRyan M. Confer                               Sincerely,
Comapany NameGenprex, Inc.
                                                               Division of
Corporation Finance
September 17, 2019 Page 2                                      Office of
Healthcare & Insurance
FirstName LastName